Lundbeck has great expectations for new antibody: "This could be the new generation of migraine drugs"

The pharmaceutical firm thinks Lu AG0922 could be the backbone of a new generation of migraine treatments and has launched several studies in the hope of targeting a broader indication, Head of R&D at Lundbeck Johan Luthman tells MedWatch.

Johan Luthman, head of Research and Development at Lundbeck | Photo: PR / Lundbeck

Pharmaceutical firm Lundbeck's Laboratories are buzzing, busy with the work spearheaded by the company's Head of Research and Development Johan Luthman, as a new generation of migraine drugs are taking shape.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs